PLX Insider Trading Activity and SEC Form 4 Filings
PLX insider trading summary
Over the past 12 months, insiders at Protalix BioTherapeutics, Inc. (PLX) reported 1 open-market purchase worth $101K by 1 insider and 1 sale worth $314 by 1 insider on SEC Form 4. Net insider buying was $101K.
Latest PLX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 19, 2025 | Dror Bashan | President and CEO | Buy | $101K (56,000 @ $1.81) |
| Nov 18, 2025 | Amos Bar-Shalev | Insider | Sell | $314 (168 @ $1.87) |
| Jun 10, 2025 | Aharon Schwartz | Insider | Buy | $206K (129,000 @ $1.60) |
| Oct 19, 2023 | Dror Bashan | President and CEO | Buy | $23K (16,129 @ $1.41) |
| Oct 19, 2023 | Dror Bashan | President and CEO | Buy | $68K (48,387 @ $1.40) |
| Jan 3, 2023 | Aharon Schwartz | Director | Buy | $156K (110,000 @ $1.42) |
| Apr 11, 2022 | Dror Bashan | President and CEO | Buy | $102K (68,000 @ $1.50) |
| Jun 3, 2021 | Dexcel Pharma Technologies Ltd. | 10% Owner | Sell | $1.9M (857,506 @ $2.25) |
| Jun 3, 2021 | Dan Oren | 10% Owner | Sell | $1.9M (857,506 @ $2.25) |
| Jun 2, 2021 | Dexcel Pharma Technologies Ltd. | 10% Owner | Sell | $157K (61,211 @ $2.56) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.